BDSX vs GH
BDSX: Biodesix provides AI-enabled, blood-based diagnostic solutions for lung disease, offering actionable insights that guide personalized treatment and improve patient outcomes. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | BDSX | GH | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $23.87 | $162.59 | |
| Market cap | $252M | $21.8B | |
| Net margin FY2025, SEC XBRL | -39.8% | -42.4% | BDSX higher |
| Operating margin FY2025, SEC XBRL | -31.5% | -44.5% | BDSX higher |
| ROA FY2025, SEC XBRL | -40.3% | -20.7% | GH higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 5.47 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +24.1% | +32.9% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +29.8% | BDSX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.35 | 1.23 | |
| 1-year return as of 2026-10-20 close | +260.6% | +131.6% | BDSX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.